目次

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. List Of Primary Sources

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. India Active Pharmaceutical Ingredients Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Increasing geriatric population
3.4.2. Rising prevalence of target diseases such as hospital-acquired infections, genetic, cardiovascular, and neurological diseases
3.4.3. Increasing preference for targeted therapy approach in cancer treatment
3.4.4. Increasing preference for outsourcing APIs
3.5. Market Restraint Analysis
3.5.1. High capital investments and production cost
3.5.2. Stringent Safety and handling regulations regarding APIs
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis

Chapter 4. India Active Pharmaceutical Ingredients Market: Type of Synthesis Estimates & Trend Analysis
4.1. India Active Pharmaceutical Ingredients Market: Type of Synthesis Segment Dashboard
4.2. India Active Pharmaceutical Ingredients Market: Type of Synthesis Movement Analysis
4.3. India Active Pharmaceutical Ingredients Market Size & Trend Analysis, by Type of Synthesis, 2018 to 2030 (USD Billion)
4.4. Biotic APIs
4.4.1. Biotic APIs Market, 2018 - 2030 (USD Billion)
4.4.1.1. Biotech APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
4.4.1.2. Generic APIs
4.4.1.2.1. Generic APIs Market, 2018 - 2030 (USD Billion)
4.4.1.3. Innovative APIs
4.4.1.3.1. Innovative APIs Market, 2018 - 2030 (USD Billion)
4.4.1.4. Biotech APIs Market, By Product (Revenue, USD Billion, 2018 - 2030)
4.4.1.5. Monoclonal Antibodies
4.4.1.5.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Billion)
4.4.1.6. Hormones
4.4.1.6.1. Hormones Market, 2018 - 2030 (USD Billion)
4.4.1.7. Cytokines
4.4.1.7.1. Cytokines Market, 2018 - 2030 (USD Billion)
4.4.1.8. Recombinant Proteins
4.4.1.8.1. Recombinant Proteins Market, 2018 - 2030 (USD Billion)
4.4.1.9. Therapeutic Enzymes
4.4.1.9.1. Therapeutic Enzymes Market, 2018 - 2030 (USD Billion)
4.4.1.10. Vaccines
4.4.1.10.1. Vaccines Market, 2018 - 2030 (USD Billion)
4.4.1.11. Blood Factors
4.4.1.11.1. Blood Factors Market, 2018 - 2030 (USD Billion)
4.5. Synthetic APIs
4.5.1. Synthetic APIs Market, 2018 - 2030 (USD Billion)
4.5.1.1. Synthetic APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
4.5.1.2. Generic APIs
4.5.1.2.1. Generic APIs Market, 2018 - 2030 (USD Billion)
4.5.1.3. Innovative APIs
4.5.1.3.1. Innovative APIs Market, 2018 - 2030 (USD Billion)

Chapter 5. India Active Pharmaceutical Ingredients Market: Type of Manufacturer Estimates & Trend Analysis
5.1. India Active Pharmaceutical Ingredients Market: Type of Manufacturer Segment Dashboard
5.2. India Active Pharmaceutical Ingredients Market: Type of Manufacturer Movement Analysis
5.3. India Active Pharmaceutical Ingredients Market Size & Trend Analysis, by Type of Manufacturer, 2018 to 2030 (USD Billion)
5.4. Captive APIs
5.4.1. Captive APIs Market, 2018 - 2030 (USD Billion)
5.5. Merchant APIs
5.5.1. Merchant APIs Market, 2018 - 2030 (USD Billion)

Chapter 6. India Active Pharmaceutical Ingredients Market: Type Estimates & Trend Analysis
6.1. India Active Pharmaceutical Ingredients Market: Type Segment Dashboard
6.2. India Active Pharmaceutical Ingredients Market: Type Movement Analysis
6.3. India Active Pharmaceutical Ingredients Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Billion)
6.4. Generic APIs
6.4.1. Generic APIs Market, 2018 - 2030 (USD Billion)
6.5. Innovative APIs
6.5.1. Innovative APIs Market, 2018 - 2030 (USD Billion)

Chapter 7. India Active Pharmaceutical Ingredients Market: Application Estimates & Trend Analysis
7.1. India Active Pharmaceutical Ingredients Market: Application Segment Dashboard
7.2. India Active Pharmaceutical Ingredients Market: Application Movement Analysis
7.3. India Active Pharmaceutical Ingredients Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Billion)
7.4. Cardiovascular Diseases
7.4.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Billion)
7.5. Oncology
7.5.1. Innovative APIs Oncology Market, 2018 - 2030 (USD Billion)
7.6. CNS and Neurology
7.6.1. CNS and Neurology Market, 2018 - 2030 (USD Billion)
7.7. Orthopedic
7.7.1. Orthopedic Market, 2018 - 2030 (USD Billion)
7.8. Endocrinology
7.8.1. Endocrinology Market, 2018 - 2030 (USD Billion)
7.9. Pulmonology
7.9.1. Pulmonology Market, 2018 - 2030 (USD Billion)
7.10. Gastroenterology
7.10.1. Gastroenterology Market, 2018 - 2030 (USD Billion)
7.11. Nephrology
7.11.1. Nephrology Market, 2018 - 2030 (USD Billion)
7.12. Ophthalmology
7.12.1. Ophthalmology Market, 2018 - 2030 (USD Billion)
7.13. Others
7.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. India Active Pharmaceutical Ingredients Market: Type of Drug Estimates & Trend Analysis
8.1. Active Pharmaceutical Ingredients Market: Type of Drug Movement Analysis
8.2. Prescription
8.2.1. Prescription Market, 2018 - 2030 (USD Billion)
8.2.1.1. OTC
8.2.1.2. OTC Market, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Active Pharmaceutical Ingredients Market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Dr. Reddy’s Laboratories Ltd.
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Sun Pharmaceutical Industries Ltd.
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. Teva Pharmaceutical Industries Ltd.
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Cipla Inc.
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. AbbVie Inc.
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Aurobindo Pharma
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. Sandoz International GmbH (Novartis AG)
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Viatris Inc.
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. Fresenius Kabi AG
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. STADA Arzneimittel AG
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.3.11. Lonza
9.3.3.11.1. Company Overview
9.3.3.11.2. Financial Performance
9.3.3.11.3. Product Benchmarking
9.3.3.11.4. Strategic Initiatives
9.3.3.12. Curia
9.3.3.12.1. Company Overview
9.3.3.12.2. Financial Performance
9.3.3.12.3. Product Benchmarking
9.3.3.12.4. Strategic Initiatives
9.3.3.13. Pfizer Inc.
9.3.3.13.1. Company Overview
9.3.3.13.2. Financial Performance
9.3.3.13.3. Product Benchmarking
9.3.3.13.4. Strategic Initiatives
9.3.3.14. Bristol-Myers Squibb Company
9.3.3.14.1. Company Overview
9.3.3.14.2. Financial Performance
9.3.3.14.3. Product Benchmarking
9.3.3.14.4. Strategic Initiatives
9.3.3.15. Merck KGaA
9.3.3.15.1. Company Overview
9.3.3.15.2. Financial Performance
9.3.3.15.3. Product Benchmarking
9.3.3.15.4. Strategic Initiatives
9.3.3.16. Catalent, Inc.
9.3.3.16.1. Company Overview
9.3.3.16.2. Financial Performance
9.3.3.16.3. Product Benchmarking
9.3.3.16.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others

List of Tables
Table 1 India Active Pharmaceutical Ingredients Market, By Country, 2018 - 2030 (USD Billion)
Table 2 India Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
Table 3 India Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
Table 4 India Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
Table 5 India Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
Table 6 India Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Active pharmaceutical ingredients market segmentation
Fig. 8 Market driver relevance analysis (Current & future impact)
Fig. 9 Market restraint relevance analysis (Current & future impact)
Fig. 10 Market challenge relevance analysis (Current & future impact)
Fig. 11 Penetration & growth prospect mapping
Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 13 Porter’s Five Forces analysis
Fig. 14 Market penetration vs growth prospect mapping
Fig. 15 Active pharmaceutical ingredients market: Type of synthesis movement analysis
Fig. 16 Biotech APIs market, 2018 - 2030 (USD Billion)
Fig. 17 Synthetic APIs market, 2018 - 2030 (USD Billion)
Fig. 18 Active pharmaceutical ingredients market: Type of manufacturer movement analysis
Fig. 19 Captive APIs market, 2018 - 2030 (USD Billion)
Fig. 20 Merchant APIs market, 2018 - 2030 (USD Billion)
Fig. 21 Active pharmaceutical ingredients market: Type movement analysis
Fig. 22 Generic APIs market, 2018 - 2030 (USD Billion)
Fig. 23 Innovative APIs market, 2018 - 2030 (USD Billion)
Fig. 24 Active pharmaceutical ingredients market: Application movement analysis
Fig. 25 Cardiovascular diseases market, 2018 - 2030 (USD Billion)
Fig. 26 Oncology market, 2018 - 2030 (USD Billion)
Fig. 27 CNS and Neurology market, 2018 - 2030 (USD Billion)
Fig. 28 Orthopaedic market, 2018 - 2030 (USD Billion)
Fig. 29 Endocrinology market, 2018 - 2030 (USD Billion)
Fig. 30 Pulmonology market, 2018 - 2030 (USD Billion)
Fig. 31 Gastroenterology market, 2018 - 2030 (USD Billion)
Fig. 32 Nephrology market, 2018 - 2030 (USD Billion)
Fig. 33 Ophthalmology market, 2018 - 2030 (USD Billion)
Fig. 34 Others market, 2018 - 2030 (USD Billion)
Fig. 35 Active pharmaceutical ingredients market: Type of drug movement analysis
Fig. 36 Prescription market, 2018 - 2030 (USD Billion)
Fig. 37 OTC market, 2018 - 2030 (USD Billion)
Fig. 38 Regional marketplace: Key takeaways
Fig. 39 Regional outlook, 2018 & 2030